FIELD: chemistry.
SUBSTANCE: invention relates to a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in the chemical formula 1 X1 constitutes N-R1 or S, X2 constitutes CH or N, R1 constitutes ethyl, isobutyl, cyclopropyl, cyclopentyl or 2-((tert-butoxycarbonyl)amino)ethyl, R 2 constitutes hydrogen or halogen, and R 3 constitutes hydrogen or C1-5alkyl. The invention also relates to a specific compound, a pharmacologically acceptable salt or a stereoisomer thereof presented in the claims.
EFFECT: compounds according to the invention are intended for producing a pharmaceutical composition for prevention or treatment of an inflammatory disease, autoimmune disease, proliferative disease, hyperproliferative disease, immunity-mediated disease, cancer or tumour mediated by an inhibitory effect against JAK 3 and BTK kinases.
6 cl, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| DERIVATIVES OF OXIFLUOROPIPERIDINE AS A KINASE INHIBITOR | 2018 |
|
RU2758370C1 |
| DERIVATIVES OF AMINOFLUORPIPERIDINE AS A KINASE INHIBITOR | 2018 |
|
RU2762637C1 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2017 |
|
RU2757457C2 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| INHIBITING JAK COMPOUNDS BASED ON PYRAZOLOPYRIMIDINE AND METHODS | 2010 |
|
RU2675857C2 |
| HETEROARYL DERIVATIVE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, A METHOD FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAID ACTIVE SUBSTANCE | 2016 |
|
RU2719367C2 |
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
